Breakthroughs in Upper Gastrointestinal Tumours – Insights from ESMO 2024.
White Paper based on late-breaking abstracts presented in Barcelona.
Upper gastrointestinal (GI) tumours, including hepatocellular carcinoma (HCC), gastric cancer, and esophageal cancer, were a major focus at ESMO 2024, with sessions dedicated to advancing therapeutic strategies, improving patient outcomes, and addressing quality-of-life concerns.
This white paper explores breakthroughs in the treatment of upper digestive gastrointestinal tumours presented at the conference, including innovations in immunotherapy combinations, precision treatments, and multimodal approaches. It emphasizes the critical role of real-world evidence (RWE) in addressing persistent challenges such as treatment resistance, toxicity management, and recurrence. Additionally, it highlights how RWE can refine treatment strategies, enhance personalization, and improve outcomes for patients with upper digestive gastrointestinal cancers.
To download the white paper, please complete the following form.